Oncolytics Biotech (ONCY) Earnings Analysis

Oncolytics Biotech (ONCY) next reports earnings on 2026-08-14, consensus EPS -0.07 USD. Last quarter (2026-05-14) it missed with EPS -0.08 USD vs -0.05 USD est (-60%). It has beaten estimates in 4/6 recent quarters (67%). Trailing P/E -3.46.

Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades

When does ONCY next report earnings?

Next earnings date2026-08-14
Consensus EPS estimate-0.07 USD
Revenue estimaten/a

ONCY earnings history — beats and misses

Quarter (report date)EPS actualEPS est.SurpriseResult
2026-05-14-0.08 USD-0.05 USD-60%Miss
2026-03-30-0.08 USD-0.06 USD-33.3%Miss
2025-11-12-0.1 USD-0.12 USD+16.7%Beat
2025-08-08-0.05 USD-0.11 USD+54.5%Beat
2025-03-07-0.07 USD-0.08 USD+12.5%Beat
2024-08-01-0.07 USD-0.08 USD+12.5%Beat

Beat rate: 4/6 (67%) over reported quarters with consensus data.

ONCY valuation and analyst view

Trailing P/E-3.46
Trailing EPS-0.31634 USD
Price / book-25.51
Dividend yield0.00%
Market cap0.08B
Analyst consensusBuy (8 buy / 2 hold / 0 sell)

Related research pages

Frequently asked questions

When is Oncolytics Biotech (ONCY)'s next earnings date?

Oncolytics Biotech is next scheduled to report on 2026-08-14, with a consensus EPS estimate of -0.07 USD.

Did ONCY beat earnings last quarter?

In its 2026-05-14 report, ONCY posted EPS of -0.08 USD versus a -0.05 USD estimate — a miss of 60%.

What is ONCY's earnings track record?

Over the last 6 reported quarters with consensus data, ONCY beat estimates 4 times (67%).

What is ONCY's current P/E ratio and EPS?

ONCY trades at a trailing P/E of -3.46 on trailing EPS of -0.31634155450290263 USD.

What do analysts rate ONCY?

Analyst consensus is "Buy" across 10 ratings (0 strong buy, 8 buy, 2 hold, 0 sell, 0 strong sell).